DARE
Dare Bioscience, Inc.
Next earnings Aug 12, 2026 · consensus $-0.25 EPS
Last earnings +0.7% on 2026-05-14
$2.09
▲ +4.50%$2.09▼ -18.36%
over 1Y
L $1.30EODHDH $3.27
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.5%
1W+2.0%
1M-10.3%
3M+34.8%
YTD+7.2%
1Y-18.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 10429.4% YoY; but unprofitable (net margin -1300.7%).
Revenue (FY2025) $1.03M · FY2025
Dare Bioscience, Inc. shows $1.03M in FY2025 revenue (+10429.4% YoY), a -1300.7% net margin, and -471.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $10.0M | $2.81M | $9.78K | $1.03M |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.1M | -$31.4M | -$30.9M | -$23.5M | -$13.6M |
| Net income | -$38.7M | -$30.9M | -$30.2M | -$4.05M | -$13.4M |
| Diluted EPS | -$0.63 | -$0.37 | -$4.15 | -$0.48 | -$1.20 |
| Net margin | — | -309.5% | -1074.2% | -41430.9% | -1300.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.72M
EV / EBITDA—
EV / Sales5.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-44.0%
FCF yield-33.8%
Quality & risk
ROIC (est.)-376.6%
Free cash flow-$10.3M
Total debt—
Net cash$24.7M
Altman Z-Score-8.74 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+64.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗S-8Filing2026-06-23open ↗8-KPeriod ending 2026-06-222026-06-22open ↗8-KPeriod ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-11open ↗4Period ending 2026-06-112026-06-11open ↗4Period ending 2026-06-112026-06-11open ↗4Period ending 2026-06-112026-06-11open ↗4Period ending 2026-06-112026-06-11open ↗DEFA14AFiling2026-06-01open ↗DEFA14AFiling2026-06-01open ↗8-KPeriod ending 2026-05-142026-05-18open ↗253G2Filing2026-05-15open ↗
Frequently asked
- Is Dare Bioscience, Inc. (DARE) a buy?
- DARE currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 10429.4% YoY; but unprofitable (net margin -1300.7%).
- What is Dare Bioscience, Inc.'s quality score?
- DARE scores 34.56862745098039/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001401914, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:15:02 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.